Incyte Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Incyte ha aumentado sus beneficios a una tasa media anual de 25.1%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 15.5% anual. Los ingresos han ido creciendo a una tasa media de 13.2% al año. La rentabilidad financiera de Incyte es de 13.8%, y sus márgenes netos son de 19.8%.

Información clave

20.9%

Tasa de crecimiento de los beneficios

20.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	12.8%
Rentabilidad financiera	3.2%
Margen neto	2.5%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07

Recent updates

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Apr 14

Desglose de ingresos y gastos

Cómo gana y gasta dinero Incyte. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:INCY Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	3,857	97	1,165
31 Mar 24	3,768	745	1,143
31 Dec 23	3,696	598	1,159
30 Sep 23	3,609	425	1,138
30 Jun 23	3,513	366	1,136
31 Mar 23	3,470	324	1,105
31 Dec 22	3,395	341	999
30 Sep 22	3,331	876	954
30 Jun 22	3,320	945	879
31 Mar 22	3,115	933	796
31 Dec 21	2,986	949	741
30 Sep 21	2,913	535	682
30 Jun 21	2,721	338	612
31 Mar 21	2,703	478	561
31 Dec 20	2,667	-296	518
30 Sep 20	2,457	-335	487
30 Jun 20	2,388	-191	469
31 Mar 20	2,229	-376	457
31 Dec 19	2,159	447	469
30 Sep 19	2,108	405	441
30 Jun 19	2,006	306	435
31 Mar 19	1,997	253	437
31 Dec 18	1,882	109	435
30 Sep 18	1,798	-109	424
30 Jun 18	1,729	-102	419
31 Mar 18	1,534	-167	401
31 Dec 17	1,536	-313	367
30 Sep 17	1,419	-155	363
30 Jun 17	1,306	-154	348
31 Mar 17	1,226	-107	324
31 Dec 16	1,106	104	302
30 Sep 16	1,023	151	260
30 Jun 16	941	74	231
31 Mar 16	858	49	216
31 Dec 15	754	7	197
30 Sep 15	634	-86	193
30 Jun 15	644	13	184
31 Mar 15	581	-33	174
31 Dec 14	511	-48	166
30 Sep 14	485	-54	155
30 Jun 14	372	-136	142
31 Mar 14	374	-101	125
31 Dec 13	355	-83	110
30 Sep 13	372	-21	96

Ingresos de calidad: INCY tiene una única gran ganancia de $131.5M que afecta a sus resultados financieros de los últimos 12 meses de 30th June, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio(2.5%) de INCY son inferiores a los del año pasado (10.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lINCY han crecido significativamente en un 25.1% al año.

Acelerando crecimiento: INCY ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: INCY tuvo un crecimiento negativo de los beneficios (-73.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-21.1%).

Incyte Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Recent updates

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia